OCV-C02

N/A

Report date: 2024/06/27 20:00:09

Base Information

Drug NameOCV-C02
Drug Alias NameOCV-C02OCV-103/104OCV-104/103OCV-103/OCV-104OCV-104/OCV-103
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionImmunostimulantsE3 ubiquitin-protein ligase RNF43 modulatorsWnt signalling pathway modulators +[4] 
TargetsE3 ubiquitin-protein ligase RNF43Mitochondrial import receptor subunit TOM34
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOncotherapy Science, Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOtsuka Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A